- Trials with a EudraCT protocol (1,346)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (164)
1,346 result(s) found for: lymphoma.
Displaying page 42 of 68.
EudraCT Number: 2012-004053-88 | Sponsor Protocol Number: EuroNet-PHL-C2 | Start Date*: 2015-07-01 |
Sponsor Name:Justus-Liebig-University Giessen | ||
Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents | ||
Medical condition: Hodgkin lymphoma in children and adolescents | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) NL (Completed) DK (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004848-36 | Sponsor Protocol Number: BAY80-6946/17119 | Start Date*: 2015-05-05 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and ... | |||||||||||||
Medical condition: patients with relapsed or refractory diffuse large B cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002739-14 | Sponsor Protocol Number: ACT14596 | Start Date*: 2016-12-07 | ||||||||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | ||||||||||||||||||
Full Title: Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients with Relapsed or Refractory T-acute Lymphoblastic Leukemia ... | ||||||||||||||||||
Medical condition: Haematological malignancy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005811-16 | Sponsor Protocol Number: OMB110913 | Start Date*: 2008-12-22 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia | ||
Medical condition: Chronic Lymphocytic Leukaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) DE (Completed) GR (Completed) IT (Completed) ES (Completed) GB (Completed) BG (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002848-32 | Sponsor Protocol Number: M-2017-322 | Start Date*: 2018-05-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Miltenyi Biomedicine GmbH | |||||||||||||||||||||||||||||||||
Full Title: A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies. | |||||||||||||||||||||||||||||||||
Medical condition: Pediatric and adult patients with relapsed/refractory (r/r) CD19-expressing B cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004288-11 | Sponsor Protocol Number: ADCT-402-201 | Start Date*: 2018-08-10 |
Sponsor Name:ADC Therapeutics SA | ||
Full Title: A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | ||
Medical condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004977-12 | Sponsor Protocol Number: MO19872 | Start Date*: 2006-06-22 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy. | ||
Medical condition: Follicular non Hodgkin's Lymphoma (NHL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002100-83 | Sponsor Protocol Number: BH29812 | Start Date*: 2016-05-12 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN C... | |||||||||||||
Medical condition: Relapsed or refractory (R/R) follicular lymphoma or diffuse large B-cell lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002620-32 | Sponsor Protocol Number: CCR3862 | Start Date*: 2013-04-02 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line t... | |||||||||||||
Medical condition: Relapsed or refractory diffuse large B-cell lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001641-33 | Sponsor Protocol Number: PETAL-Studie | Start Date*: 2007-07-25 |
Sponsor Name:Universitätsklinikum Essen | ||
Full Title: Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas) | ||
Medical condition: Aggressive non-Hodgkin's lymphomas (first line therapy) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003703-62 | Sponsor Protocol Number: FIL_DEVEC | Start Date*: 2017-04-27 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas. | |||||||||||||
Medical condition: B-Cell lymphomas | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003277-22 | Sponsor Protocol Number: FIL_FOLL19 | Start Date*: 2021-10-04 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymphoma. A randomized, open label, phase III study by Fondazi... | |||||||||||||
Medical condition: High tumor burden Follicular Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003668-11 | Sponsor Protocol Number: E7080-G000-604 | Start Date*: 2018-07-30 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored... | ||||||||||||||||||||||||||||||||||||||
Medical condition: solid tumors or lymphomas, as defined in parent protocol | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005923-42 | Sponsor Protocol Number: TACL2008-002/ITCC033 | Start Date*: 2013-04-09 | ||||||||||||||||
Sponsor Name:TACL | ||||||||||||||||||
Full Title: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC | ||||||||||||||||||
Medical condition: relapsed T-ALL, T-NHL | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) AT (Prematurely Ended) GB (Completed) IT (Prematurely Ended) FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002950-38 | Sponsor Protocol Number: MK-3475-051 | Start Date*: 2014-11-10 |
Sponsor Name:Merck Sharp & Dohme LLC | ||
Full Title: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051) | ||
Medical condition: Treatment of advanced melanoma or advanced, relapsed or refractory PD-L1 positive malignant solid tumor or lymphoma in children from 6 months to less than 18 years old. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003206-41 | Sponsor Protocol Number: LOXO-BTK-20030(J2N-OX-JZNU) | Start Date*: 2022-08-03 | |||||||||||
Sponsor Name:Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) CZ (Trial now transitioned) PT (Prematurely Ended) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005324-10 | Sponsor Protocol Number: CT-P10_3.4 | Start Date*: 2015-08-20 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma | |||||||||||||
Medical condition: Low Tumour Burden Follicular Lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LV (Completed) ES (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001039-29 | Sponsor Protocol Number: GO40515 | Start Date*: 2019-02-26 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR ... | |||||||||||||
Medical condition: B-Cell Non-Hodgkin Lymphoma (B-cell NHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005197-10 | Sponsor Protocol Number: VT3996-202 | Start Date*: 2021-10-01 | |||||||||||
Sponsor Name:Viracta Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | |||||||||||||
Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004151-39 | Sponsor Protocol Number: 0761-007 | Start Date*: 2012-03-16 | |||||||||||
Sponsor Name:Kyowa Hakko Kirin Pharma, Inc. | |||||||||||||
Full Title: Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL) | |||||||||||||
Medical condition: Treatment of patients with relapsed or refractory PTCL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
